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Abstract
Objective To assess the risk of adverse cardiovascular events in women
who discontinue hormone replacement therapy after myocardial infarction
compared with those who continue.
Design Nationwide register based cohort study.
Setting All hospitals in Denmark.
Population All 3322 women aged 40 years or over who survived 30
days after a myocardial infarction and were prescribed hormone
replacement therapy at the time of myocardial infarction in the period
1997 to 2008.
Main outcome measures Reinfarction, cardiovascular mortality, and
all cause mortality 30 to 360 days after discharge.
Results A total of 282 (8.5%) women had a reinfarction, 218 (6.6%)
died of cardiovascular causes, and 357 (10.7%) died of any cause during
follow-up. Women who discontinued overall hormone replacement
therapy in the first year after myocardial infarction did not have a
significantly different risk of reinfarction (hazard ratio 0.90, 95%
confidence interval 0.68 to 1.19), cardiovascular mortality (1.21, 0.90 to
1.62), or all cause mortality (1.22, 0.97 to 1.53) than women who
continued use. However, discontinuation of vaginal oestrogen was
associated with a lower risk of reinfarction (hazard ratio 0.54, 0.34 to
0.86).
Conclusion No certain conclusions can be drawn regarding increased
or decreased risk of adverse cardiovascular events with continuing
hormone replacement therapy after myocardial infarction. The results
rule out neither a modest benefit nor a worrisome increase in risk. These
figures may be valuable when a possible cardiovascular risk of hormone
replacement therapy needs to be balanced with menopausal symptoms
for the individual patient.
Introduction
Hormone replacement therapy (HRT) was recommended for
prevention of coronary artery disease until the end of the 1990s
because several observational studies had shown a
cardioprotective effect of HRT.
1-3 However, in 1998 the Heart
and Estrogen Replacement Study evaluated the role of HRT
compared with placebo for secondary prevention of coronary
arterydiseaseandfoundnosignificantdifferencesintheprimary
outcome of cardiac death or myocardial infarction, and in 2001
the Women’s Health Initiative study of HRT for primary
prevention was stopped prematurely when an increased risk of
coronary artery disease in women using HRT was found.
4 5 As
a result, guidelines now recommend that HRT should not be
used for primary or secondary prevention of coronary artery
disease.
6-8
Oestrogen has favourable effects on endothelial function, as
well as inflammatory and haemostatic mechanisms.
9 However,
these effects and the blood concentrations of respective
hormones differ between different types of HRT and routes of
administration,andtheydisappearrapidlyafterdiscontinuation
ofHRT.
10-17DiscontinuationofHRTcanbetroublesomeowing
to rebound climacteric symptoms, and this is particularly
problematic in women diagnosed as having coronary artery
disease while using HRT, as guidelines for this situation
recommend discontinuation of HRT although evidence on the
risk-benefit of this strategy is lacking.
18-21 Indeed, the period
afteramyocardialinfarctionisapathophysiologicallyvulnerable
time, with endothelial dysfunction, elevated inflammatory
markers, and so on, and potential rebound effects on these
mechanisms of discontinuation of HRT may be more prone to
cause adverse cardiovascular events in this period.
22-24 We have
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Research
RESEARCHpreviously shown that in spite of current recommendations for
discontinuationofHRTaftermyocardialinfarction,around80%
of women in Denmark using HRT at the time of myocardial
infarction continue HRT after discharge.
25
The aim of this study was therefore to assess whether women
who discontinue HRT after myocardial infarction have a lower
risk of reinfarction, cardiovascular death, or all cause death in
the first year after myocardial infarction than do women who
continue HRT.
Methods
AllcitizensinDenmarkhaveauniquecivilregistrationnumber
that enables linkage of nationwide registers at an individual
level.TheDanishnationalpatientregisterholdsinformationon
all admissions to Danish hospitals since 1978 registered by
diagnoses according to the World Health Organization’s
international classification of diseases (ICD). Operations are
classified according to the Danish classification of operation
until 1996 and according to the Nordic Medico-Statistical
Committee’s classification of surgical procedures from 1997.
26
The Danish national prescription register holds information on
all prescriptions dispensed by Danish pharmacies since 1995.
Prescriptionsarecodedaccordingtotheanatomictherapeutical
chemical (ATC) system. All residents in Denmark are covered
by a national health security system and have the cost of drugs
partially reimbursed.
27 All pharmacies are therefore required to
register all dispensed prescriptions. All deaths are registered in
the central population register within 14 days of occurrence.
Population
We identified all women who were aged 40 years or older on
1 January 1997 and discharged with a diagnosis of myocardial
infarction (ICD-8 code 410, ICD-10 codes I21 to I22) in the
period 1997 to 2008 in the national patient register. The
diagnosisofmyocardialinfarctioninthisregisterhaspreviously
been validated and has a sensitivity of 91% and a positive
predictive value of 93%.
28 We included women who were still
alive 30 days after discharge (fig 1⇓). As a measure of
socioeconomic status, we calculated the yearly household
income as an average of the income in the five years before
admission, where possible, and divided it into thirds of income.
We excluded all women who migrated to or from Denmark in
the study period 1997 to 2008.
Use of hormone replacement therapy
We identified all claimed prescriptions for HRT in the Danish
register of medicinal product statistics (ATC codes G03C,
G03D, G03F, G03XC and G02BA03) in the study period. We
did not include drugs usually used for contraceptive purposes,
exceptforaprogesteroneintrauterinedevicewhichiscommonly
usedbypostmenopausalwomen.HRTcoversabroadspectrum
ofchemicalcompounds,formulations,routesofadministration,
anddosages.Wedividedthispharmacologicalmultiplicityinto
four categories (table 1⇓): oestrogen alone, combinations of
oestrogenandprogestogen,vaginaloestrogenalone,and“other
HRT.” These categories were mutually exclusive. We used the
“otherHRT”categorytoensurethatalltreatmentintervalscould
be included in the analyses, not because of similarities of the
treatments in this group.
The register includes information about dispensing date,
strength, and quantity of the prescription. Indication and daily
drug dosage are not included in the register, so we estimated
the daily drug dose by calculating the average drug dose of up
tothreeconsecutiveprescriptionsbeforetheactualprescription
and not using information on future prescriptions in the
calculations. This method has previously been described in
detail.
29Onthebasisoftheseassumptions,wecalculatedperiods
when HRT was available and we defined patients as receiving
HRT if it was available. Similarly, we defined discontinuation
of any of the four categories if no treatment was available in
the specific category of HRT. We defined discontinuation of
overall HRT if no treatment was available in any of the four
categories. Thus, each woman could contribute with HRT
treatmentordiscontinuationperiodsseveraltimes.Foranalyses
ofthefourHRTcategories,wefollowedwomenaslongasthey
did not change to a different category of HRT. We calculated
exposure to and discontinuation of HRT for all prescriptions in
the entire period from 1 January 1996 to 31 December 2008.
This means that any discontinuation beginning in the first 30
days after discharge was registered and included in the analysis
asadiscontinuationifitcontinuedbeyondthefirst30daysafter
discharge (which was the beginning of the follow-up time).
Concomitant drugs and comorbidity
We defined concomitant drugs as claimed prescriptions within
180 days before or 30 days after the myocardial infarction for
β blockers (ATC code C07), angiotensin converting enzyme
inhibitors/angiotensin II receptor blockers (ATC code C09),
statins (ATC code C10AA), and clopidogrel (ATC code
B01AC04).WedefinedcomorbiditywiththemodifiedOntario
acute myocardial infarction prediction rules by diagnosis from
the index admission and one year before admission.
30 31 The
national registers have a low sensitivity for the diagnosis of
heart failure, and they hold no information about left ventricle
ejection fraction.
32 We therefore used prescriptions for loop
diuretics (ATC code C03C) as a proxy for heart failure, as
previously done.
33 Similarly, we used prescriptions for glucose
lowering drugs (ATC code A10) as a proxy for drug treated
diabetes. We also obtained information about previous
myocardialinfarction,revascularisation(percutaneouscoronary
intervention (operation codes 30350, 30354, and KFNG) and
coronary artery bypass graft surgery (operation codes 30009 to
30199 and KFNA to KFNE)).
Outcomes
We defined reinfarction as fatal or non-fatal myocardial
infarction (ICD-10 codes I21 to I22) at least 30 days after
discharge for the index myocardial infarction as done
previously.
34 We defined cardiovascular death as death due to
adiseaseofthecirculatorysystem(ICD10-codeI00toI99)and
all cause death as death of any cause. Follow-up was from day
30 until 1 year after discharge.
Statistical analysis
We present baseline characteristics of the different groups of
women as numbers with percentages or medians with
interquartile ranges and compared them by using χ
2 tests and
analysis of variance. We categorised age into groups of 40-59
years, 60-69 years, 70-79 years, and 80 years and above (table
2⇓).
We calculated unadjusted incidence rates for reinfarction,
cardiovascular mortality, and all cause mortality for
discontinuation of and continued treatment with overall HRT
and the four categories of HRT. We divided duration of
discontinuation of HRT into 1-90 days, 91-180 days, 181-360
days, and 1-360 days. We did calculations and analyses for the
periods 30-90 days, 91-180 days, 181-360 days, and 30-360
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RESEARCHdaysafterdischarge.WeusedamultivariableCoxproportional
hazards model to calculate hazard ratios for reinfarction,
cardiovascular mortality, and all cause mortality for various
periods of discontinuation. We did this for both overall HRT
and the four HRT categories, using continued treatment as the
reference. The multivariable Cox model was adjusted for age
group, year of myocardial infarction, comorbidity (previous
myocardial infarction, revascularisation within 30 days of
myocardialinfarction,cerebrovasculardisease,congestiveheart
failure,malignancy,cardiacdysrhythmias,chronicrenalfailure,
acute renal failure, diabetes with complications, pulmonary
oedema, shock), concomitant use of drugs (β blockers,
angiotensinconvertingenzymeinhibitors,statins,loopdiuretics,
clopidogrel, glucose lowering drugs), and income group. We
tested the model assumptions and found them to be valid. We
did tests for interactions for the various periods of
discontinuation of the HRT groups and age groups, year of
myocardial infarction, revascularisation within 30 days after
myocardial infarction, comorbidity, previous myocardial
infarction, and concomitant drugs and for year of myocardial
infarction and age groups. No interactions were evident, so we
included no interactions in the final Cox model.
For all statistical analyses, we considered a level of 5% to be
statisticallysignificant.WeusedSASstatisticalsoftwareversion
9.2 and Stata version 11 for all analyses. The study was
conducted and reported in accordance with the Strengthening
the Reporting of Observational Studies in Epidemiology
(STROBE) recommendations.
35
Sensitivity analyses
To make sure that the exclusion of women who died during the
first 30 days after discharge did not seriously affect our results,
wedidsensitivityanalysesofcardiovasculardeathandallcause
death including these women and beginning follow-up at the
day of discharge. We estimated the effect of an unmeasured
confounderaccordingtothe“ruleout”approachfortherelevant
reported results.
36
Results
A total of 44 099 women aged 40 or over on 1 January 1997
had a myocardial infarction in the period 1997 to 2008, but 10
494ofthesewomendiedduringthefirst30daysafterdischarge
and were therefore excluded, as were the 71 women lost to
follow-up (fig 1⇓). Among the remaining 33 534 women, 3322
(9.9%) were using HRT at the time of myocardial infarction,
and these women constituted the population of this study. The
number of reinfarctions during follow-up was 282 (8.5%), 357
(10.7%) women died of all causes, and 218 (6.6%) died of
cardiovascular causes.
Most women used the combination of systemic oestrogen and
progestogen(1100;33.1%),followedbyvaginaloestrogen(977,
29.4%) and systemic oestrogen alone (954, 28.7%). Only 291
(8.8%)womenusedHRTbelongingtothecategory“otherHRT”
(table 2⇓). Baseline characteristics of women using different
categories of HRT were very different, as is evident from table
2⇓ and as we have previously found.
25
Analyses of discontinuation in the first 30-360 days after
myocardial infarction showed an association between
discontinuation of vaginal oestrogen and a decreased risk of
reinfarction (hazard ratio 0.54, 95% confidence interval 0.34 to
0.86),aswellasaninsignificantassociationfordiscontinuation
of systemic oestrogen (0.56, 0.28 to 1.11) and overall HRT
(0.90, 0.68 to 1.19) (table 3⇓). We also found a statistically
insignificant increase in cardiovascular mortality (hazard ratio
1.39, 0.73 to 2.66, for discontinuation of systemic oestrogen;
1.15,0.78to1.72,forvaginaloestrogen;and1.21,0.90to1.62,
foroverallHRT)andallcausemortality(hazardratio1.17,0.70
to 1.94, for discontinuation of systemic oestrogen; 1.31, 0.95
to1.83,forvaginaloestrogen;and1.22,0.97to1.53,foroverall
HRT).
When analysing the different durations of discontinuation, we
found that discontinuation of overall HRT for 1-90 days was
associated with an increased risk of cardiovascular mortality
and all cause mortality but no increased risk of reinfarction (fig
2⇓). This increased risk was apparent for cardiovascular
mortality only when discontinuation occurred in the period
30-90 days after discharge (hazard ratio 1.90, 1.15 to 3.12) and
forallcausemortalityinboththeperiods30-90days(1.58,1.04
to 2.39) and 91-180 days after discharge (1.76, 1.08 to 2.87).
For 1-90 days of discontinuation of systemic oestrogen alone,
wefoundincreasedcardiovascularmortality(hazardratio6.14,
1.95 to 19.3) and all cause mortality (3.23, 1.30 to 8.07) during
the first 30-90 days after discharge (fig 2⇓). Again, we found a
statistically insignificant lower risk of reinfarction. For 1-90
days of discontinuation of vaginal oestrogen, we found a
decreased risk of reinfarction during the first 30-90 days after
discharge (hazard ratio 0.36, 0.16 to 0.82) (fig 2⇓). For all the
above,thecorrespondingunadjustedincidenceratesofcontinued
and discontinued treatment were equivalent to the proportional
hazardanalyses(tables3⇓,4⇓,5⇓,and6⇓).Fordiscontinuation
of combinations of oestrogen and progestogen and for the
category “other HRT,” calculations were limited owing to very
few endpoints (table 3⇓, fig 2⇓).
Tables 7⇓ and 8⇓ show the results of the sensitivity analyses.
Theassociationsbetweendiscontinuationandtheendpointsdid
not change significantly after inclusion of the first 30 days in
theanalysesorafterpostponementofthetimeofdiscontinuation
by seven or 14 days.
Unmeasured confounding
Totestwhetherthelowriskofreinfarctionafterdiscontinuation
of vaginal oestrogen found in both the first year and the first
30-90 days after myocardial infarction could be due to
unmeasured confounding, we tried to estimate the hypothetical
size of such an unmeasured confounder, assuming a 20%
prevalence of an unmeasured confounder in the population and
a prevalence of discontinuation of 20%.
36 The results indicate
that an unmeasured confounder would be very unevenly
distributed between the groups and have a very strong
association with continued treatment (fig 3⇓ and fig 4⇓). A
confounder or combination of confounders that could decrease
the risk of reinfarction from 1.00 to 0.54 for discontinuation in
thefirstyearaftermyocardialinfarctionwouldhavetoincrease
the risk fivefold (fig 3⇓) and thereby exceed the effects of any
measured confounder in the study, such as diabetes or age 80
orover.However,torendertheresultsstatisticallyinsignificant,
a confounder would have to increase the risk only twofold. In
thecaseofdiscontinuationofvaginaloestrogeninthefirst30-90
days after myocardial infarction, a confounder would have to
increasetherisklessthantwofoldtomaketheresultstatistically
insignificant (fig 4⇓).
Discussion
This study is to our knowledge the first to look at whether
women in a real life population who discontinue hormone
replacement therapy after myocardial infarction have a lower
risk of adverse cardiovascular events than do women who
continue using HRT and whether discontinuation of different
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RESEARCHcategoriesofHRTmightcarrydifferentrisks.Ourmainfinding
was that in women with myocardial infarction who followed
treatment guidelines and discontinued HRT overall, we could
not detect a decreased or increased risk of reinfarction,
cardiovascular mortality, or all cause mortality during the first
year after the index myocardial infarction. Discontinuation of
vaginal oestrogen after myocardial infarction was associated
with a decrease in risk of reinfarction in the first year and the
first30-90daysafterdischarge.Womeninthevaginaloestrogen
group had very different baseline characteristics and higher
incidence rates compared with women in the other HRT
categories, which is relevant in interpreting these results.
Comparison with other studies
Most trials of the cardiovascular efficacy and safety of HRT
have used oral conjugated equine oestrogens with or without
medroxyprogesteroneacetatedependingonwhetherthewoman
hadanintactuterus,buttheuseofconjugatedequineoestrogens
inourpopulationwasverylimited.
4 5 25HRTcoversamultitude
of hormones, formulations, doses, and routes of administration
andhasfavourableeffectsonendothelialfunction,serumlipids,
lipoproteins, and markers of fibrinolysis, inflammation, and
coagulation.
9 37 These effects differ, however, between oral and
transdermal oestrogen, probably because of the hepatic first
passeffectwithoraloestrogen.
10-13Vaginaloestrogentreatment
was previously believed to have only local effects, but a recent
study showed a fivefold increase in serum oestradiol after one
weekofvaginaltreatment.
14Interestingly,arecentobservational
study in Denmark found no overall effect of oral HRT on risk
of coronary artery disease, but both transdermal and vaginal
HRT were associated with decreased risk.
38 Our results, too,
seem to imply that vaginal oestrogen has a systemic effect or,
alternatively, that some unmeasured confounder is responsible
for the observed difference. As this is an observational study,
we can only speculate about, and not explain, what causes the
observed lower risk of reinfarction in women who discontinue
vaginal oestrogen.
WehavepreviouslyfoundinapopulationofwomenusingHRT
at the time of myocardial infarction in the period 1997 to 2005
that more than 80% of women who survived one year after
myocardial infarction claimed a new prescription for HRT in
the first year after discharge.
25 The vast majority of women
continued use of the same category of HRT that they used at
the time of myocardial infarction. This low rate of
discontinuationmightbebecausemostwomenwhodiscontinue
HRT experience serious discomfort such as hot flushes and
sleep disorders, which have a negative effect on their quality of
life.Likewise,discontinuationofHRTcanbeespeciallydifficult
for women on long term HRT or for those who previously had
severeclimactericsymptoms.
18-20 39Discontinuationoflongterm
HRT may lead to increases in plasminogen activator inhibitor
1 and to augmented endothelial dysfunction in women with
coronary artery disease. Also, blood concentrations of low
density lipoprotein cholesterol and total cholesterol increase in
women who discontinue HRT.
17 These findings suggest that
discontinuation of HRT might cause a detrimental rebound
effectthatmaycontributetoadversecardiovascularevents.The
period immediately after myocardial infarction is a
pathophysiologicallyvulnerabletimewindow,withendothelial
dysfunction and elevated inflammatory markers. Hence, a
possible rebound effect of discontinuation of HRT on these
mechanisms might be especially detrimental during this
period.
22-24Thatthepost-infarctionperiodmaynotbetheoptimal
time to discontinue HRT would therefore seem plausible. The
results reported here, in which discontinuation seems to have a
greater effect in the first 30-90 days after myocardial infarction,
suggest that this line of reasoning may be true.
Only a few studies have examined the effect of HRT on
prognosis after myocardial infarction. An observational study
of women admitted with myocardial infarction found that
women using HRT at the time of admission had significantly
lower in-hospital mortality than did women who did not use
HRT and concluded that this could be explained by therapeutic
effects of HRT, selection bias, or both.
40 Among women who
used HRT at the time of coronary artery stenting, repeat
revascularisation has also been reported to be significantly
reduced.
41 Our study illustrates the importance of future
randomised studies in this area concerning the use and
discontinuation of HRT; however, adequately powered studies
of this sort seem unlikely ever to be done.
Strengths and limitations
The main strength of this study is the complete and nationwide
cohort of unselected women using HRT at the time of
myocardialinfarction,includinginformationaboutconcomitant
drugs and comorbidity. The required registration by the Danish
pharmacies and the reimbursement of medical expenses ensure
that all social classes and women both in and out of the labour
market were represented. Moreover, we were able to include
women using all the formulations of HRT available on the
market.
The study has several limitations inherent to its observational
nature. We have no information on clinical parameters such as
obesity and smoking status, and although the incorporation of,
for example, concomitant drugs, comorbidity, and income in
our analyses might capture some effects of the important
cardiovascular risk factors that we lack information about in
this study, we cannot rule out unmeasured confounding. The
significantlylowerriskofreinfarctionseenafterdiscontinuation
of vaginal oestrogen might be due to unmeasured confounding
even though such a confounder or combination of confounders
would have to be highly prevalent and carry a great risk. The
HRT doses and treatment durations were calculated
approximations, and the true dates of beginning and
discontinuing a treatment may differ from the calculated dates.
Thesensitivityanalysesinwhichdiscontinuationwaspostponed
for seven and 14 days did not alter the direction of the results,
and discontinuation has previously been assessed using
prescriptions and the same algorithm for calculating treatment
intervals and discontinuation as in our study.
42 However, we
cannotruleoutthepossibilityofunmeasuredfactorsinfluencing
our calculations, as the accuracy of assessment of
discontinuationbymonitoringofprescriptionsisunknown.We
lack information about the precise indications for use or
discontinuation of HRT and about symptoms that may be a
confounder, as hot flushes may be a marker of increased
cardiovascular risk.
43 Furthermore, the well known observation
that discontinuation of drugs as well as of placebo is associated
with increased mortality must clearly be considered for a
balanced interpretation of our results.
44 45
Conclusion
The main result of this study is that we found no certain
increased or a decreased risk of reinfarction or death with
continuing HRT after a myocardial infarction. The 95%
confidence limits rule out neither a modest benefit nor a
worrisome increase in risk. These figures are valuable when a
possible cardiovascular risk needs to be balanced with
menopausal symptoms for the individual patient.
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RESEARCHWhat is already known on this topic
Guidelines recommend discontinuation of HRT after myocardial infarction, even though randomised trials have not found an increase
in cardiovascular risk in women with coronary heart disease
However, around 80% of women do not follow these guidelines
What this study adds
No certain increased or decreased risk of reinfarction or death with continuing HRT after a myocardial infarction was found
These figures are valuable when a possible cardiovascular risk needs to be balanced with menopausal symptoms for the individual
patient
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RESEARCHTables
Table 1| Categories of hormone replacement therapy (HRT)
Anatomical therapeutic chemical system codes HRT category
G03C A03, G03C A04, G03C A53, G03C A57 1. Systemic oestrogen (oral, intramuscular, nasal, or transdermal
administration)
Continuous: G03F A01, G03F A11, G03F A12, G03F A15, G0F A17; cyclic: G03F B01 ,
G03F B05, G03F B06, G03F B09, G03F B11, G03H B01. Or oestrogen from category 1 +
progestogen from category 4
2. Systemic oestrogen and progestogen, continuous or cyclic*
(oestrogen: oral, intramuscular, nasal, or transdermal administration;
progestogen: intrauterine, transdermal, or oral administration)
Vaginal tablet: G03C A03, G03C A04, G03C A57, G03C B01; vaginal ring: G03C A03; vaginal
cream: G03C A04
3. Vaginal oestrogen
Progestogen intrauterine device: G02B A03; raloxifene: G03X C01; tibolone: G03D C05,
G03C X01; progestogen alone: G03D A02, G03D A04, G03D B01, G03D C02, G03D C03.
Or any combination of categories 1 and 3 or 2 and 3
4. Other HRT
*Continuous combined oestrogen/progestogen: daily doses of both oestrogen and progestogen; cyclic combined oestrogen/progestogen: daily doses of oestrogen
and intermittent periods with daily doses of progestogen.
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RESEARCHTable 2| Baseline characteristics. Values are numbers (percentages) unless stated otherwise
P value for
difference
Other HRT at time
of MI
Vaginal oestrogen at
time of MI
Systemic oestrogen
and progestogen at
time of MI
Systemic oestrogen
at time of MI
Overall HRT at time
of MI Characteristic
between
groups*
291 (8.8) 977 (29.4) 1100 (33.1) 954 (28.7) 3322 No of women
<0.001 68 (58-77) 79 (72-84) 63 (57-71) 71 (63-79) 70 (61-79) Median (interquartile range)
age (years)
Age group (years):
<0.001 82 (28.2) 40 (4.1) 386 (35.1) 175 (18.3) 683 (20.6) 40-59
74 (25.4) 155 (15.9) 411 (37.4) 251 (26.3) 891 (26.8) 60-69
83 (28.5) 325 (33.3) 242 (22.0) 314 (32.9) 963 (29.0) 70-79
52 (17.9) 457 (46.8) 61 (5.6) 214 (22.4) 784 (23.6) ≥80
Year of MI:
<0.001 46 (15.8) 202 (20.7) 348 (31.6) 276 (28.9) 872 (26.3) 1997-9
112 (38.5) 274 (28.1) 388 (35.3) 323 (33.9) 1097 (33.0) 2000-2
83 (25.8) 293 (30.0) 266 (24.2) 247 (25.9) 889 (26.8) 2003-5
50 (17.2) 208 (21.3) 98 (8.9) 108 (11.3) 464 (14.0) 2006-8
Comorbidity:
0.001 22 (7.6) 113 (11.6) 75 (6.8) 99 (10.4) 309 (9.3) Previous MI
<0.001 88 (30.2) 202 (20.7) 351 (31.9) 221 (23.2) 862 (26.0) Revascularisation within
30 days
<0.001 7 (2.4) 49 (5.0) 17 (1.6) 28 (2.9) 101 (3.0) Cerebrovascular disease†
0.009 6 (2.1) 43 (4.4) 22 (2.0) 35 (3.7) 106 (3.2) Congestive heart failure†
0.38 6 (2.1) 23 (2.4) 15 (1.4) 16 (1.7) 60 (1.8) Malignancy†
0.002 9 (3.1) 56 (5.7) 28 (2.6) 41 (4.3) 134 (4.0) Cardiac dysrhythmias†
0.006‡ 1 (0.3) 11 (1.1) 3 (0.3) 1 (0.1) 16 (0.5) Chronic renal failure†
0.25‡ 0 (0.0) 4 (0.4) 1 (0.1) 1 (0.1) 6 (0.2) Acute renal failure†
0.30 4 (1.4) 11 (1.1) 6 (0.6) 6 (0.6) 27 (0.8) Diabetes with
complications†
0.29‡ 2 (0.7) 3 (0.3) 6 (0.6) 1 (0.1) 12 (0.4) Pulmonary oedema†
0.02‡ 1 (0.3) 9 (0.9) 2 (0.2) 1 (0.1) 13 (0.4) Shock†
Concomitant drugs:
0.77 176 (60.5) 576 (59.0) 670 (60.9) 563 (59.0) 1985 (59.8) β blockers
0.04 134 (46.1) 432 (44.2) 428 (38.9) 405 (42.5) 1399 (42.1) ACE inhibitors
0.02 134 (46.1) 365 (37.4) 468 (42.6) 389 (40.8) 1356 (40.8) Statins
<0.001 99 (34.0) 447 (45.8) 306 (27.8) 364 (38.2) 1216 (36.6) Loop diuretics
0.06 103 (35.4) 278 (28.5) 345 (31.4) 269 (28.2) 995 (30.0) Clopidogrel
<0.001 28 (9.6) 122 (12.5) 74 (6.7) 87 (9.1) 311 (9.4) Glucose lowering drugs
Income group:
58 (19.9) 304 (31.1) 164 (14.9) 199 (20.9) 725 (21.8) 1
<0.001 73 (25.1) 328 (33.6) 264 (24.0) 296 (31.0) 961 (28.9) 2
160 (55.0) 345 (35.3) 672 (61.1) 459 (48.1) 1636 (49.3) 3
ACE=angiotensin converting enzyme; HRT=hormone replacement therapy; MI=myocardial infarction.
*χ
2 test for categorical variables and analysis of variance for continuous variables.
†According to modified Ontario acute myocardial infarction prediction rules.
‡χ
2 test may not be valid owing to very few observations.
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RESEARCHTable 3| Hazard ratios and unadjusted incidence rates for discontinuation in first year after myocardial infarction
All cause death Cardiovascular death Reinfarction
Continued
treatment Discontinuation
Continued
treatment Discontinuation
Continued
treatment Discontinuation
Hormone replacement therapy overall
Reference 1.22 (0.97 to 1.53) Reference 1.21 (0.90 to 1.62) Reference 0.90 (0.68 to 1.19) Hazard ratio* (95% CI)
119.2 156.3 74.2 91.9 112.9 90.9 Incidence rate†
238 119 148 70 216 66 No of events
1995.8 761.6 1995.8 761.6 1912.5 725.7 Person years
Systemic oestrogen
Reference 1.17 (0.70 to 1.94) Reference 1.39 (0.73 to 2.66) Reference 0.56 (0.28 to 1.11) Hazard ratio* (95% CI)
111.1 126.2 60.6 80.3 116.1 58.7 Incidence rate†
66 22 36 14 66 10 No of events
594.0 174.3 594.0 174.3 568.5 170.5 Person years
Systemic oestrogen and progestogen
Reference 0.96 (0.53 to 1.75) Reference 0.94 (0.37 to 2.39) Reference 0.30 (0.09 to 0.96) Hazard ratio* (95% CI)
83.7 89.0 33.4 43.4 85.9 16.9 Incidence rate†
60 16 31 6 59 3 No of events
716.8 179.8 716.8 179.8 686.8 177.9 Person years
Vaginal oestrogen
Reference 1.31 (0.95 to 1.83) Reference 1.15 (0.78 to 1.72) Reference 0.54 (0.34 to 0.86) Hazard ratio* (95% CI)
189.4 212.5 136.8 139.7 168.4 78.1 Incidence rate†
80 73 59 47 68 26 No of events
422.3 343.5 422.3 343.5 403.8 332.8 Person years
Other hormone replacement therapy
Reference 1.00 (0.24 to 4.28) Reference 0.60 (0.03 to 11.8) Reference 0.11 (0.01 to 2.20) Hazard ratio* (95% CI)
115.0 101.2 25.5 63.9 105.7 26.3 Incidence rate†
18 4 10 1 16 1 No of events
156.5 39.2 156.5 39.2 151.3 38.0 Person years
*Multivariable Cox proportional hazards analysis adjusted for age group, year of myocardial infarction (MI), comorbidity (previous MI, revascularisation within 30
days of MI, cerebrovascular disease, congestive heart failure, malignancy, cardiac dysrhythmias, chronic renal failure, acute renal failure, diabetes with complications,
pulmonary oedema, shock), concomitant use of drugs (β blockers, angiotensin converting enzyme inhibitors, statins, loop diuretics, clopidogrel, glucose lowering
drugs), and income; no interactions were found or included in the model.
†Unadjusted event rates per 1000 person years.
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RESEARCHTable 4| Unadjusted incidence rates of reinfarction, cardiovascular mortality, and all cause mortality for discontinuation of HRT overall
All cause mortality Cardiovascular mortality Reinfarction
HRT discontinued
Continued
HRT
HRT discontinued
Continued
HRT
HRT discontinued
Continued
HRT
181-360
days
91-180
days 1-90 days
181-360
days
91-180
days 1-90 days
181-360
days
91-180
days 1-90 days
30-90 days after myocardial infarction
– – 349.9 180.8 – – 257.3 116.7 – – 198.5 237.7 Incidence
rate*
– – 34 79 – – 25 51 – – 19 102 Failures
– – 97.2 436.9 – – 97.2 436.9 – – 95.7 429.2 Person
years
91-180 days after myocardial infarction
– 171.0 210.8 104.7 – 97.7 105.4 80.3 – 63.4 157.1 108.9 Incidence
rate*
– 14 24 60 – 8 12 46 – 5 17 60 Failures
– 81.9 113.9 573.0 – 81.9 113.9 573.0 – 78.9 108.2 551.2 Person
years
181-360 days after myocardial infarction
105.5 105.8 87.4 100.4 50.2 60.5 51.0 51.7 31.8 80.4 69.4 57.9 Incidence
rate*
21 14 12 99 10 8 7 51 6 10 9 54 Failures
199.1 132.3 137.3 986.0 199.1 132.3 137.3 986.0 188.8 124.4 129.7 932.1 Person
years
HRT=hormone replacement therapy.
*Unadjusted incidence rates per 1000 person years.
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RESEARCHTable 5| Unadjusted incidence rates of reinfarction, cardiovascular mortality and all cause mortality for discontinuation of systemic
oestrogen
All cause mortality Cardiovascular mortality Reinfarction
HRT discontinued
Continued
HRT
HRT discontinued
Continued
HRT
HRT discontinued
Continued
HRT
181-360
days
91-180
days 1-90 days
181-360
days
91-180
days 1-90 days
181-360
days
91-180
days
1-90
days
30-90 days after myocardial infarction
– – 382.0 151.1 – – 327.4 75.5 – – 109.7 184.5 Incidence
rate*
– – 7 20 – – 6 10 – – 2 24 Failures
– – 18.3 132.3 – – 18.3 132.3 – – 18.2 130.1 Person
years
91-180 days after myocardial infarction
– 59.9 173.7 117.8 – 59.9 69.5 88.3 – NA 36.0 116.0 Incidence
rate*
– 1 5 20 – 1 2 15 – 0 1 19 Failures
– 16.7 28.8 169.8 – 16.7 28.8 169.8 – 16.6 27.8 163.8 Person
years
181-360 days after myocardial infarction
87.5 90.8 63.0 89.1 43.7 60.5 31.5 37.7 22.0 125.0 65.8 83.8 Incidence
rate*
4 3 2 26 2 2 1 11 1 4 2 23 Failures
45.7 33.0 31.8 291.9 45.7 33.0 31.8 291.9 45.4 32.0 30.4 274.5 Person
years
HRT=hormone replacement therapy.
*Unadjusted incidence rates per 1000 person years.
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RESEARCHAll cause mortality Cardiovascular mortality Reinfarction
HRT discontinued
Continued
HRT
HRT discontinued
Continued
HRT
HRT discontinued
Continued
HRT
181-360
days
91-180
days 1-90 days
181-360
days
91-180
days 1-90 days
181-360
days
91-180
days
1-90
days
30-90 days after myocardial infarction
– – 371.2 284.7 – – 282.9 213.5 – – 124.2 343.0 Incidence
rate*
– – 21 28 – – 16 21 – – 7 33 Failures
– – 56.6 98.4 – – 56.6 98.4 – – 56.4 96.2 Person
years
91 to 180 days after myocardial infarction
– 236.3 260.1 200.9 – 128.9 173.4 160.7 – 107.7 90.9 184.9 Incidence
rate*
– 11 12 25 – 6 8 20 – 5 4 22 Failures
– 46.5 46.1 124.4 – 46.5 46.1 124.4 – 46.4 44.0 119.0 Person
years
181 to 360 days after myocardial infarction
146.2 187.4 119.0 135.3 83.5 104.1 79.3 90.2 42.4 88.9 42.7 68.9 Incidence
rate*
14 9 6 27 8 5 4 18 4 4 2 13 Failures
95.8 48.0 50.4 199.5 95.8 48.0 50.4 199.5 94.3 45.0 46.8 188.6 Person
years
Table 6 Unadjusted incidence rates of reinfarction, cardiovascular mortality, and all cause mortality for discontinuation of vaginal oestrogen
HRT=hormone replacement therapy.
*Unadjusted incidence rates per 1000 person years.
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RESEARCHTable 7| Sensitivity analysis: hazard ratios (95% CI) for discontinuation* after inclusion in analyses of women who died in first 30 days
after myocardial infarction
Vaginal oestrogen Systemic oestrogen and progestogen Systemic oestrogen HRT overall Death
1.17 (0.83 to 1.65) 1.01 (0.48 to 2.14) 1.47 (0.86 to 2.52) 1.24 (0.96 to 1.62) Cardiovascular death
1.30 (0.98 to 1.73) 1.02 (0.61 to 1.70) 1.30 (0.85 to 2.00) 1.26 (1.02 to 1.54) All cause death
HRT=hormone replacement therapy.
*Discontinuation 1-360 days after MI myocardial infarction.
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RESEARCHTable 8| Sensitivity analysis: hazard ratios (95% CI) for discontinuation* after postponement of discontinuation date by 7 and 14 days
All cause death Cardiovascular death Reinfarction Postponement
HRT overall:
1.14 (0.90 to 1.44) 1.09 (0.80 to 1.48) 0.91 (0.69 to 1.22) 7 days
1.12 (0.89 to 1.43) 1.02 (0.74 to 1.39) 0.86 (0.63 to 1.15) 14 days
Systemic oestrogen:
1.17 (0.70 to 1.97) 1.34 (0.69 to 2.61) 0.54 (0.26 to 1.11) 7 days
1.18 (0.70 to 2.00) 1.30 (0.66 to 2.69) 0.51 (0.24 to 1.09) 14 days
Vaginal oestrogen:
1.14 (0.82 to 1.60) 0.94 (0.62 to 1.41) 0.50 (0.31 to 0.80) 7 days
1.11 (0.79 to 1.53) 0.86 (0.56 to 1.30) 0.48 (0.30 to 0.79) 14 days
HRT=hormone replacement therapy.
*Discontinuation in 1-360 days after MI myocardial infarction.
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RESEARCHFigures
Fig 1 Study population
Fig 2 Hazard ratios (95% CI) for reinfarction, cardiovascular mortality, and all cause mortality for discontinuation of hormone
replacement therapy (HRT) overall and HRT categories. Hazard ratios are for discontinuation with continued use as
reference. Multivariable Cox proportional hazards analysis was adjusted for age group, year of myocardial infarction (MI),
comorbidity (previous MI, revascularisation within 30 days of MI, cerebrovascular disease, congestive heart failure,
malignancy, cardiac dysrhythmias, chronic renal failure, acute renal failure, diabetes with complications, pulmonary oedema,
shock), concomitant drug use (β blockers, angiotensin converting enzyme inhibitors, statins, loop diuretics, clopidogrel,
glucose lowering drugs), and income. No interactions were found or included in model
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RESEARCHFig 3 Required size of unmeasured confounder to fully explain decrease in risk from 1.00 to 0.54 (solid blue line) and to
render results statistically insignificant (dashed red line), assuming prevalence of confounder of 20% in population and
prevalence of discontinuation of 20%
Fig 4 Required size of unmeasured confounder to fully explain decrease in risk from 1.00 to 0.41 (solid blue line) and to
render results statistically insignificant (dashed red line), assuming prevalence of confounder of 20% in population and
prevalence of discontinuation of 20%
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